172MO Novel regulators of antigen presentation and therapeutic reactivation of MHC-I to overcome immune evasion in small cell lung cancer
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine cancer and the addition of immune checkpoint blockade (ICB) to first-line chemotherapy for SCLC has shown modest benefits. SCLCs evade anti-tumor immunity by repressing MHC-I expression and antigen presentation (AP). We comprehensively analyzed SCLC clinical samples to identify SCLC molecular subtypes associated with MHC repression.
Authors
- Deniz Demircioğlu (ORCID: https://orcid.org/0000-0001-7857-0407)
- Sohini Chakraborty (ORCID: https://orcid.org/0000-0002-6339-7792)
- B. Halmos
- Andrew Elliott (ORCID: https://orcid.org/0000-0001-8494-8031)
- Ari M. Vanderwalde (ORCID: https://orcid.org/0000-0002-6842-2563)
- Triparna Sen (ORCID: https://orcid.org/0000-0003-4673-7481)
- Dan Hasson (ORCID: https://orcid.org/0000-0001-7943-1636)
- Vrinda Jethalia
Institutions
- Montefiore Medical Center (US)
- Caris Life Sciences (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100925
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00